|
1
|
Torre LA, Siegel RL and Jemal A: Lung
cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Akhurst T: Staging of Non-Small-Cell Lung
Cancer. PET Clin. 13:1–10. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Valentino F, Borra G, Allione P and Rossi
L: Emerging targets in advanced non-small-cell lung cancer. Future
Oncol. 14:61–72. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr..Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Heist RS and Engelman JA: SnapShot:
Non-small cell lung cancer. Cancer Cell. 21:448.e22012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang X, Zheng Q, Wang C, Zhou H, Jiang G,
Miao Y, Zhang Y, Liu Y, Li Q, Qiu X and Wang E: CCDC106 promotes
non-small cell lung cancer cell proliferation. Oncotarget.
8:26662–26670. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou X, Xu X, Gao C and Cui Y: XIST
promote the proliferation and migration of non-small cell lung
cancer cells via sponging miR-16 and regulating CDK8 expression. Am
J Transl Res. 11:6196–6206. 2019.PubMed/NCBI
|
|
9
|
Peng H, Pan X, Su Q, Zhu LS and Ma GD:
MiR-372-3p promotes tumor progression by targeting LATS2 in
colorectal cancer. Eur Rev Med Pharmacol Sci. 23:8332–8344.
2019.PubMed/NCBI
|
|
10
|
Shi C, Yang Y, Zhang L, Yu J, Qin S, Xu H
and Gao Y: MiR-200a-3p promoted the malignant behaviors of ovarian
cancer cells through regulating PCDH9. Onco Targets Ther.
12:8329–8338. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang Z, Zhang L, Wang B, Wei R, Wang Y,
Wan J, Zhang C, Zhao L, Zhu X, Zhang Y, et al: MiR-337-3p
suppresses proliferation of epithelial ovarian cancer by targeting
PIK3CA and PIK3CB. Cancer Lett. 469:54–67. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen Y, Gao DY and Huang L: In vivo
delivery of miRNAs for cancer therapy: Challenges and strategies.
Adv Drug Deliv Rev. 81:128–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu X, Ban Y, Zhao Z, Pan Q and Zou J:
MicroRNA-1298-3p inhibits proliferation and invasion of glioma
cells by downregulating Nidogen-1. Aging (Albany NY). 12:2020.(Epub
ahead of print).
|
|
14
|
Wu X: Expressions of miR-21 and miR-210 in
breast cancer and their predictive values for prognosis. Iran J
Public Health. 49:21–29. 2020.PubMed/NCBI
|
|
15
|
Wang J, Shu H and Guo S: MiR-646
suppresses proliferation and metastasis of non-small cell lung
cancer by repressing FGF2 and CCND2. Cancer Med. Apr 29–2020.(Epub
ahead of print). View Article : Google Scholar
|
|
16
|
Qiu Z, Li H, Wang J and Sun C: miR-146a
and miR-146b in the diagnosis and prognosis of papillary thyroid
carcinoma. Oncol Rep. 38:2735–2740. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yuan Z, Baker K, Redman MW, Wang L, Adams
SV, Yu M, Dickinson B, Makar K, Ulrich N, Bohm J, et al: Dynamic
plasma microRNAs are biomarkers for prognosis and early detection
of recurrence in colorectal cancer. Br J Cancer. 117:1202–1210.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bie LY, Li N, Deng WY, Lu XY, Guo P and
Luo SX: Serum miR-191 and miR-425 as diagnostic and prognostic
markers of advanced gastric cancer can predict the sensitivity of
FOLFOX chemotherapy regimen. Onco Targets Ther. 13:1705–1715. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xia J, Li D, Zhu X, Xia W, Qi Z, Li G and
Xu Q: Upregulated miR-665 expression independently predicts poor
prognosis of lung cancer and facilitates tumor cell proliferation,
migration and invasion. Oncol Lett. 19:3578–3586. 2020.PubMed/NCBI
|
|
20
|
Xing Z, Li S, Liu Z, Zhang C and Bai Z:
CTCF-induced upregulation of HOXA11-AS facilitates cell
proliferation and migration by targeting miR-518b/ACTN4 axis in
prostate cancer. Prostate. 80:388–398. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng J, Sadot E, Vigidal JA, Klimstra DS,
Balachandran VP, Kingham TP, Allen PJ, D'Angelica MI, DeMatteo RP,
Jarnagin WR and Ventura A: Characterization of hepatocellular
adenoma and carcinoma using microRNA profiling and targeted gene
sequencing. PLoS One. 13:e02007762018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang W, Zhao LJ, Tan YX, Ren H and Qi ZT:
MiR-138 induces cell cycle arrest by targeting cyclin D3 in
hepatocellular carcinoma. Carcinogenesis. 33:1113–1120. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liang W, Li X, Li Y, Li C, Gao B, Gan H,
Li S, Shen J, Kang J, Ding S, Lin X and Liao L: Gallic acid induces
apoptosis and inhibits cell migration by upregulating miR-518b in
SW1353 human chondrosarcoma cells. Int J Oncol. 44:91–98. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang M, Zhou S, Zhang L, Zhang J, Cai H,
Zhu J, Huang C and Wang J: miR-518b is down-regulated, and involved
in cell proliferation and invasion by targeting Rap1b in esophageal
squamous cell carcinoma. FEBS Lett. 586:3508–3521. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu C, Zheng Y, Lian D, Ye S, Yang J and
Zeng Z: Analysis of microRNA expression profile identifies novel
biomarkers for non-small cell lung cancer. Tumori. 101:104–110.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Singletary SE, Allred C, Ashley P, Bassett
LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, et
al: Staging system for breast cancer: Revisions for the 6th edition
of the AJCC cancer staging manual. Surg Clin North Am. 83:803–819.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chu GCW, Lazare K and Sullivan F: Serum
and blood based biomarkers for lung cancer screening: A systematic
review. BMC Cancer. 18:1812018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shin VY and Chu KM: MiRNA as potential
biomarkers and therapeutic targets for gastric cancer. World J
Gastroenterol. 20:10432–10439. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Adhami M, Haghdoost AA, Sadeghi B and
Malekpour Afshar R: Candidate miRNAs in human breast cancer
biomarkers: A systematic review. Breast Cancer. 25:198–205. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hashemi ZS, Khalili S, Forouzandeh
Moghadam M and Sadroddiny E: Lung cancer and miRNAs: A possible
remedy for anti-metastatic, therapeutic and diagnostic
applications. Expert Rev Respir Med. 11:147–157. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang X and Wang P: MiR-188-5p and
MiR-141-3p influence prognosis of bladder cancer and promote
bladder cancer synergistically. Pathol Res Pract. 215:1525982019.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ning S, Liu H, Gao B, Wei W, Yang A, Li J
and Zhang L: miR-155, miR-96 and miR-99a as potential diagnostic
and prognostic tools for the clinical management of hepatocellular
carcinoma. Oncol Lett. 18:3381–3387. 2019.PubMed/NCBI
|
|
34
|
Du W, Tang H, Lei Z, Zhu J, Zeng Y, Liu Z
and Huang JA: miR-335-5p inhibits TGF-beta1-induced
epithelial-mesenchymal transition in non-small cell lung cancer via
ROCK1. Respir Res. 20:2252019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li Q, Wu X, Guo L, Shi J and Li J:
MicroRNA-7-5p induces cell growth inhibition, cell cycle arrest and
apoptosis by targeting PAK2 in non-small cell lung cancer. FEBS
Open Bio. 9:1983–1993. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ma X, Zhou J, Mo H and Ying Y: Association
of miR-100 expression with clinicopathological features and
prognosis of patients with lung cancer. Oncol Lett. 18:1318–1322.
2019.PubMed/NCBI
|
|
37
|
Mott TF: Lung Cancer: Management. FP
Essent. 464:27–30. 2018.PubMed/NCBI
|
|
38
|
Yang X, Zhang Q, Zhang M, Su W, Wang Z, Li
Y, Zhang J, Beer DG, Yang S and Chen G: Serum microRNA signature is
capable of early diagnosis for non-small cell lung cancer. Int J
Biol Sci. 15:1712–1722. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhuang Z, Sun C and Gong H: High serum
miR-484 expression is associated with the diagnosis and prognosis
of patients with non-small cell lung cancer. Exp Ther Med.
18:4095–4102. 2019.PubMed/NCBI
|
|
40
|
Zhang YL, Zhang ZL, Zhu XB, Xu L, Lu P, Xu
M, Liu WJ, Zhang XY, Yao HM and Ye XW: Low plasma miR-25 expression
is a favorite prognosis factor in non-small cell lung cancer. Eur
Rev Med Pharmacol Sci. 23:5251–5259. 2019.PubMed/NCBI
|
|
41
|
Li Y, Cui X, Li Y, Zhang T and Li S:
Upregulated expression of miR-421 is associated with poor prognosis
in non-small-cell lung cancer. Cancer Manag Res. 10:2627–2633.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hu C, Peng J, Lv L, Wang X, Zhou Y, Huo J
and Liu D: miR-196a regulates the proliferation, invasion and
migration of esophageal squamous carcinoma cells by targeting
ANXA1. Oncol Lett. 17:5201–5209. 2019.PubMed/NCBI
|
|
43
|
Arabsorkhi Z, Gharib E, Yaghmoorian
Khojini J, Farhadieh ME, Nazemalhosseini-Mojarad E and Zali MR:
miR-298 plays a pivotal role in colon cancer invasiveness by
targeting PTEN. J Cell Physiol. 235:4335–4350. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Han X, Du C, Chen Y, Zhong X, Wang F, Wang
J, Liu C, Li M, Chen S and Li B: Overexpression of miR-939-3p
predicts poor prognosis and promotes progression in lung cancer.
Cancer Biomark. 25:325–332. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Huang T, Wang G, Yang L, Peng B, Wen Y,
Ding G and Wang Z: MiR-186 inhibits proliferation, migration, and
invasion of non-small cell lung cancer cells by downregulating Yin
Yang 1. Cancer Biomark. 21:221–228. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tang X, Ding Y, Wang X, Wang X, Zhao L and
Bi H: miR-650 promotes non-small cell lung cancer cell
proliferation and invasion by targeting ING4 through
Wnt-1/β-catenin pathway. Oncol Lett. 18:4621–4628. 2019.PubMed/NCBI
|
|
47
|
Tian G, Wang SW, Song M, Hu YF, Cao XN and
Ge JW: MicroRNA-16 inhibits the proliferation, migration and
invasion of non-small cell lung carcinoma cells by down-regulating
matrix metalloproteinase-19 expression. Eur Rev Med Pharmacol Sci.
23:5260–5269. 2019.PubMed/NCBI
|
|
48
|
Kushwaha R, Thodima V, Tomishima MJ, Bosl
GJ and Chaganti RS: miR-18b and miR-518b Target FOXN1 during
epithelial lineage differentiation in pluripotent cells. Stem Cells
Dev. 23:1149–1156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ji X, Ji Y, Wang W and Xu X: Forkhead box
N1 inhibits the progression of non-small cell lung cancer and
serves as a tumor suppressor. Oncol Lett. 15:7221–7230.
2018.PubMed/NCBI
|
